More than 60 surgeons from across Europe participated in
a seminar discussing the latest data and updates on ReGen's CMI.
Professor Maurilio Marcacci, MD, PhD, of Bologna, Italy chaired the
seminar. The faculty included J.R. Steadman, MD and W. G. Rodkey, DVM
of Vail, Colorado, D. Holsten, MD of Koblenz, Germany and P.
Bulgheroni, MD of Varese, Italy.
The seminar was held during the 12th ESSKA meeting in Innsbruck,
Austria last week. ESSKA is the European Society of Sports
Traumatology, Knee Surgery and Arthroscopy.
Four presentations were made during the symposium, including an
update on the long-term follow-up of an early CMI feasibility study, a
discussion of tissue gain noted in the U.S. Multicenter Clinical
Trial, an illustration of a new all-inside suture technique being used
during some CMI procedures, and a review of morphological evolution
and MRI findings subsequent to CMI implantation.
Commenting on the event, Gerald E. Bisbee, Jr., Ph.D., Chairman
and Chief Executive Officer of ReGen Biologics said, "We were pleased
with the enthusiastic participation at this event. As use of the CMI
becomes even more widespread, and as more surgeons gain experience and
knowledge, we look forward to similar venues for surgeon interaction
and training."
The ESSKA meeting also provided an occasion for investigators to
gather and discuss the ongoing post-marketing surveillance for the
lateral CMI, which was approved for use in Europe earlier this year.
Surgeons reviewed the surgical technique, patient selection criteria,
and initial results observed in the patients treated to date.
About ReGen Biologics, Inc.:
ReGen Biologics is an orthopedic products company that develops,
manufactures and markets innovative tissue growth and repair products
for U.S. and global markets. ReGen's patented collagen scaffold
technology includes applications in orthopedics, general surgery,
spine, cardiovascular and drug delivery. The Company's first approved
product using its collagen scaffold technology is the CMI(TM), a
meniscus application of its collagen scaffold technology, which is
cleared for sale in Europe and marketed through the Company's European
subsidiary ReGen Biologics AG.
ReGen is headquartered in Franklin Lakes, NJ and manufactures its
collagen scaffold products in its ISO Certified facility located in
Redwood City, CA. For more information on ReGen, visit
www.regenbio.com.
This press release contains forward-looking statements within the
meaning of the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are based on the
current expectations and beliefs of the management of ReGen and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including those discussed in the Risk
Factors section of ReGen's 2005 annual report on Form 10-K and
additional filings with the SEC. ReGen's filings with the SEC are
available to the public at the Company's website at
http://www.regenbio.com, from commercial document-retrieval services,
and at the Web site maintained by the SEC at http://www.sec.gov.
About the European Society of Sports Traumatology, Knee Surgery
and Arthroscopy:
Please visit www.esska.org.
